Robert Hamilton, a Staff Urologic Oncologist from Princess Margaret Cancer Centre in Toronto, Canada discusses radical prostatectomy for patients with oligometastatic prostate cancer.  He overviews the clinical and biological rationale for radical prostatectomy in the oligometastases setting and highlights the role of novel imaging.  He reviews four major PET tracers receiving a lot of attention: PSMA, Axumin, Choline, and Sodium Fluoride and from an observational standpoint, Dr. Hamilton reviews a case control study that looks at ADT alone vs ADT + radical prostatectomy in the oligometastases setting.  Alan Bryce and E. David Crawford discuss radical prostectomy and other primary management avenues for oliogometastatic disease.


Biographies: Robert J. Hamilton, MD, MPH, FRCSC - Dr. Hamilton completed his medical school and urology residency at the University of Toronto. During residency he completed a Masters of Public Health (MPH) from the University of North Carolina at Chapel Hill and a research fellowship at Duke University. Before joining the faculty, he completed a fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Centre in New York City.

His clinical practice focuses on management of genitourinary malignancies, with particular focus on prostate and testis cancers. This includes minimally invasive surgical techniques. His research interests focus on the epidemiology of urological malignancies and biomarkers in risk and progression of these diseases.

E. David Crawford, MD

Read More Related Content:

Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases - results of a feasibility and case-control study

Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study

68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review